On October 14, a New York Post beauty feature promised peptide potions “reversing the signs of aging”. Its claims of effect come from three people tied to brands the story names. The headline promises time running backward. The story under it does not. “Reversing” never returns in the body; by the eighth paragraph the skin peptides “soften the appearance of expression lines”, cosmetic wording that claims a look, never a change. No study, trial, dose or measured result is named for any product. The tell is the gap between the headline’s body word and the text’s appearance word: the headline sells the cure, the paragraphs sell the look. The evidence comes from three people tied to brands in the story: Jason Diamond of Metacine, Sunbin Song of Maelove, Joe Basham of Deciem, NIOD’s parent. The first two paragraphs are about injected peptides used by celebrities, so the needle’s glamour falls on the jar. A day earlier, CNN headlined the other side of that needle: people who say injected peptides hurt them. “Buzzy” offers the crowd as proof, as if talk were a trial, and “trick” is the loaded verb, cunning in place of a measured mechanism. Outside the brands, the record is smaller. A meta-analysis of randomized trials found “modest but significant” gains, results that differ widely between studies, and oral peptides beating topical ones on most outcomes. One published topical trial followed 32 people, average age 28.5, for 28 days. A NewYork-Presbyterian dermatologist says peptide creams are cosmetics, not drugs, so they usually skip FDA approval, and calls them generally very safe. The Post’s text lists no prices and no disclosure of paid placement or link earnings.
